Hybrid study designs and the ‘inextricable link’ between RWE, epidemiology

By Melissa Fassbender contact

- Last updated on GMT

Hybrid study designs and the ‘inextricable link’ between RWE, epidemiology

Related tags: Icon, RWE, Epidemiology

Hybrid study designs can be advantageous for the generation of real world evidence, providing a potential solution to the challenges presented by observational studies.

“Real world data (RWD) and real world evidence (RWE) generation are inextricably linked to epidemiology,”​ said Kerina Bonar, epidemiologist, real world evidence, strategy and analytics, Icon Commercialisation and Outcomes.

To further discuss this link, we caught up with Bonar to examine the benefits and challenges of hybrid study designs.

Outsourcing-Pharma (OSP): What is a hybrid study and what are the advantages?

Kerina Bonar: ​Study designs are continually being evolved to meet the needs of drug development stakeholders and the wider scientific community. 

Hybrid studies are an innovation in study design that combines specific elements of particular study designs to maximise the quality and rigour of the study output.

Such innovation in study design seeks to overcome the limitations in one study design by adding features from another which serves to increase the efficiency of the study design in terms of study operationalization, time and costs.

OSP: What are the challenges? And how are they addressed?

Bonar: ​The hybrid design is a bespoke study design that needs to be tailored to each study’s research question and objectives.  

Hybrid studies can limit the involvement of the study participant and avoid the need to conduct a prospective observational study provided there is a clear understanding of the study data requirements to ensure that a hybrid study design can be leveraged.

OSP: What is the value of a cross sectional study design? How is it used with other study designs, such as medical chart review studies?

Bonar: ​The CSS design, which includes surveys and prevalence studies, is an effective study design to gather epidemiological data quickly to support drug development across the lifecycle.

CSS can be used to complement medical chart review (MCR) studies and overcome the latter study design’s dependency on routine data.

A hybrid CSS-MCR study design therefore enhances the MCR design by supplementing the data capture with the addition of a survey component which enables further data to be collected.

OSP: How is the CSS-MCR hybrid design advantageous?

Bonar: ​The hybrid CSS-MCR study design is beneficial for real world evidence (RWE) generation, and can allow for better future planning, as well as to guide the development of the next generation of real world studies.

OSP: In implementing such study designs, what are the key points to remember?

Bonar: ​Hybrid CSS-MCR studies should be designed in a well-considered manner, with the sampling strategy carefully decided at study inception.

In implementing this type of hybrid study, selection bias which can undermine the integrity of the study and robustness of the study estimates should be addressed.

Striving to employ (as far as possible) a probability sampling strategy with a passive data collection approach is recommended.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more